$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024045965 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$249.0K	$236.0K
YoY Change		5.51%	-98.42%
Cost Of Revenue		-$714.0K	$247.0K
YoY Change		-389.07%	-53.22%
Gross Profit		$963.0K	-$11.00K
YoY Change		-8854.55%	-100.08%
Gross Profit Margin		386.75%	-4.66%
Selling, General & Admin		$4.286M	$2.490M
YoY Change		72.13%	-24.18%
% of Gross Profit		445.07%
Research & Development		$9.538M	$1.249M
YoY Change		663.65%	-82.26%
% of Gross Profit		990.45%
Depreciation & Amortization		$34.00K	$50.00K
YoY Change		-32.0%	47.06%
% of Gross Profit		3.53%
Operating Expenses		$9.538M	$3.739M
YoY Change		155.09%	-63.79%
Operating Profit		-$12.86M	-$3.750M
YoY Change		242.96%	-191.58%
Interest Expense		$964.0K	-$1.553M
YoY Change		-162.07%	72.94%
% of Operating Profit
Other Income/Expense, Net		$35.88M	-$1.470M
YoY Change		-2541.09%	63.7%
Pretax Income		$23.02M	-$5.220M
YoY Change		-541.05%	-263.28%
Income Tax		-$14.00K	$8.000K
% Of Pretax Income		-0.06%
Net Earnings		$23.04M	-$5.228M
YoY Change		-540.65%	-263.78%
Net Earnings / Revenue		9251.81%	-2215.25%
Basic Earnings Per Share		$0.98	-$0.11
Diluted Earnings Per Share		-$2.83	-$0.11
COMMON SHARES
Basic Shares Outstanding	10.39M shares	1.034M shares	20.25M shares
Diluted Shares Outstanding		10.78M shares	46.76M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.86M	$10.18M
YoY Change	704.11%	-39.92%
Cash & Equivalents	$81.90M	$10.20M
Short-Term Investments
Other Short-Term Assets	$3.292M	$940.0K
YoY Change	250.21%	-19.73%
Inventory		$0.00
Prepaid Expenses
Receivables
Other Receivables	$998.0K	$1.538M
Total Short-Term Assets	$86.15M	$12.66M
YoY Change	580.53%	-34.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.674M	$2.070M
YoY Change	-19.13%	-17.43%
Goodwill	$10.50M	$14.41M
YoY Change	-27.11%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$131.0K	$130.0K
YoY Change	0.77%	-28.18%
Total Long-Term Assets	$12.31M	$16.61M
YoY Change	-25.91%	-2.84%
TOTAL ASSETS
Total Short-Term Assets	$86.15M	$12.66M
Total Long-Term Assets	$12.31M	$16.61M
Total Assets	$98.46M	$29.27M
YoY Change	236.37%	-19.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.811M	$789.0K
YoY Change	129.53%	-45.47%
Accrued Expenses	$6.792M	$5.000M
YoY Change	35.84%	-62.4%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$60.67M	$6.005M
YoY Change	910.39%	-66.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.083M	$1.456M
YoY Change	-25.62%	-18.7%
Total Long-Term Liabilities	$1.083M	$1.456M
YoY Change	-25.62%	-18.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$60.67M	$6.005M
Total Long-Term Liabilities	$1.083M	$1.456M
Total Liabilities	$75.72M	$14.58M
YoY Change	419.53%	-62.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$334.9M	-$327.0M
YoY Change	2.43%	11.21%
Common Stock	$10.00K	$192.0K
YoY Change	-94.79%	2033.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.08M	$14.70M
YoY Change
Total Liabilities & Shareholders Equity	$98.46M	$29.27M
YoY Change	236.37%	-19.91%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	$23.04M	-$5.228M
YoY Change	-540.65%	-263.78%
Depreciation, Depletion And Amortization	$34.00K	$50.00K
YoY Change	-32.0%	47.06%
Cash From Operating Activities	-$11.53M	-$6.830M
YoY Change	68.77%	-219.28%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	10.69M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-11.53M	-6.830M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	0.000	10.69M
Net Change In Cash	-11.53M	3.860M
YoY Change	-398.63%	-32.13%
FREE CASH FLOW
Cash From Operating Activities	-$11.53M	-$6.830M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$11.53M	-$6.830M
YoY Change	68.77%	-218.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	AVALO THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0705648
	dei	Entity Address Address Line1 EntityAddressAddressLine1	540 Gaither Road, Suite 400
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	City Area Code CityAreaCode	410
	dei	Local Phone Number LocalPhoneNumber	522-8707
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	AVTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7415000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	998000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	136000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10393954	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81858000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	843000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	41000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	86148000	usd
CY2024Q3	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1674000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8395000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	10502000	usd
CY2024Q3	us-gaap	Assets Assets	98455000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20993000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7304000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98455000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	342437000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-334924000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-335134000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	21076000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19693000	usd
CY2024Q3	avtx	Excess Of Initial Warrant Fair Value Over Private Placement Proceeds ExcessOfInitialWarrantFairValueOverPrivatePlacementProceeds	0	usd
CY2023Q3	avtx	Excess Of Initial Warrant Fair Value Over Private Placement Proceeds ExcessOfInitialWarrantFairValueOverPrivatePlacementProceeds	0	usd
	avtx	Excess Of Initial Warrant Fair Value Over Private Placement Proceeds ExcessOfInitialWarrantFairValueOverPrivatePlacementProceeds	79276000	usd
	avtx	Excess Of Initial Warrant Fair Value Over Private Placement Proceeds ExcessOfInitialWarrantFairValueOverPrivatePlacementProceeds	0	usd
CY2024Q3	avtx	Private Placement Transaction Costs PrivatePlacementTransactionCosts	0	usd
CY2023Q3	avtx	Private Placement Transaction Costs PrivatePlacementTransactionCosts	0	usd
	avtx	Private Placement Transaction Costs PrivatePlacementTransactionCosts	9220000	usd
CY2024Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-1100000	usd
CY2023Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	100000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-6260000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-120000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	964000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1553000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2101000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3498000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35884000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	55411000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3660000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23023000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5220000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	210000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23353000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	23037000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	249000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	236000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1353000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-714000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	247000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-453000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1505000	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9538000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1249000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16254000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11917000	usd
CY2024Q3	avtx	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	usd
CY2023Q3	avtx	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	usd
	avtx	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	27641000	usd
	avtx	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4286000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2490000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	13110000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	55450000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	21046000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12861000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3750000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-55201000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-148071000	usd
	avtx	Private Placement Transaction Costs PrivatePlacementTransactionCosts	0	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4172000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	75721000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	249000	usd
	us-gaap	Net Income Loss NetIncomeLoss	210000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23376000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-26.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-231.05
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.83
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-26.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-22.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-231.05
CY2024Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22360	shares
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	11457000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20240930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0042
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0042
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0042
CY2024Q3	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent
CY2023Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent
CY2024Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20240930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3251000	usd
CY2023Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1965000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	10502000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	131000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	131000	usd
CY2023Q4	us-gaap	Assets Assets	20993000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1811000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	446000	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7033000	usd
CY2024Q3	avtx	Warrant Liability Current WarrantLiabilityCurrent	46830000	usd
CY2023Q4	avtx	Warrant Liability Current WarrantLiabilityCurrent	0	usd
CY2024Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	5000000	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	60674000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4618000	usd
CY2024Q3	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	usd
CY2023Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	154000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	155000	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	11810000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5550000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1083000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1366000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13689000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9682374	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9682374	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	801746	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	801746	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	355990000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12008000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7624000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	3986000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-36025000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1470000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5228000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-13608000	usd
CY2024Q3	avtx	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	8648	shares
CY2024Q3	avtx	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	9799000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1848000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	23037000	usd
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	13712	shares
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1658000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	21076000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7304000	usd
	avtx	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	8648	shares
	avtx	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	9799000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2948000	usd
	us-gaap	Net Income Loss NetIncomeLoss	210000	usd
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	13712	shares
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1658000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	21076000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6969000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25939000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	953000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5228000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	14695000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10915000	usd
	avtx	Issuance Of Shares Of Common Stock And Warrants In Underwritten Public Offering Net Value IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue	13748000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32470000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	3640000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3640000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	67000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2701000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23376000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	14695000	usd
	us-gaap	Net Income Loss NetIncomeLoss	210000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23376000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	101000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	115000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2948000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2701000	usd
	avtx	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	27641000	usd
	avtx	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	usd
	avtx	Excess Of Initial Warrant Fair Value Over Private Placement Proceeds ExcessOfInitialWarrantFairValueOverPrivatePlacementProceeds	79276000	usd
	avtx	Excess Of Initial Warrant Fair Value Over Private Placement Proceeds ExcessOfInitialWarrantFairValueOverPrivatePlacementProceeds	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-148071000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	avtx	Transaction Costs From Private Placement TransactionCostsFromPrivatePlacement	7485000	usd
	avtx	Transaction Costs From Private Placement TransactionCostsFromPrivatePlacement	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-7500000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	avtx	Transaction Costs Upon Exercise Of Warrants In Private Placement TransactionCostsUponExerciseOfWarrantsInPrivatePlacement	1734000	usd
	avtx	Transaction Costs Upon Exercise Of Warrants In Private Placement TransactionCostsUponExerciseOfWarrantsInPrivatePlacement	0	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-6260000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-120000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1828000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	862000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-381000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-20000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2408000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-350000	usd
	avtx	Increase Decrease In Lease Incentives IncreaseDecreaseInLeaseIncentives	0	usd
	avtx	Increase Decrease In Lease Incentives IncreaseDecreaseInLeaseIncentives	-158000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1365000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2094000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-2110000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-8088000	usd
	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-81000	usd
	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-52000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34012000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27914000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	356000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	0	usd
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	158000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	356000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	115625000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	7485000	usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	0	usd
	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13748000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	21244000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32470000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	67000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108140000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25041000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74484000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3006000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7546000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13318000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82030000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10312000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	1925000	usd
	avtx	Issuance Of Common Stock And Series C Preferred Stock Pursant To Almata Transaction IssuanceOfCommonStockAndSeriesCPreferredStockPursantToAlmataTransaction	12272000	usd
	avtx	Issuance Of Common Stock And Series C Preferred Stock Pursant To Almata Transaction IssuanceOfCommonStockAndSeriesCPreferredStockPursantToAlmataTransaction	0	usd
	avtx	Fair Value Of Common Stock Retired In Exchange For Issuance Of Prefunded Warrants FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants	0	usd
	avtx	Fair Value Of Common Stock Retired In Exchange For Issuance Of Prefunded Warrants FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants	3640000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81858000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10180000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	41000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	131000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	131000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82030000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10312000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo Therapeutics, Inc. (the “Company,” “Avalo” or “we”) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β monoclonal antibody (“mAb”), targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo was incorporated in Delaware and commenced operation in 2011, and completed its initial public offering in October 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating and cash losses from operations. We have primarily funded our operations to date through sales of equity securities, out-licensing transactions and sales of assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, Avalo generated net income of $0.2 million and negative cash flows from operations of $34.0 million. As of September 30, 2024, Avalo had $81.9 million in cash and cash equivalents. In the first quarter of 2024, the Company closed a private placement investment consisting of an initial upfront gross investment of $115.6 million (net proceeds were $108.1 million after deducting transaction costs) and up to an additional $69.4 million of gross proceeds upon the exercise of 11,967,526 warrants issued in the financing, which expire on November 8, 2024. Subsequent to September 30, 2024 and through November 6, 2024, the Company received gross proceeds of $58.1 million from the exercise of the warrants issued in the private placement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plans, we expect that our existing cash and cash equivalents are sufficient to fund operations for at least twelve months from the filing date of this Quarterly Report on Form 10-Q and we expect current cash on hand to fund operations into at least 2027. The Company closely monitors its cash and cash equivalents and seeks to balance the level of cash and cash equivalents with our projected needs to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. We may satisfy any future cash needs through sales of equity securities under the Company’s at-the-market program or other equity financings, out-licensing transactions, strategic alliances/collaborations, sale of programs, and/or mergers and acquisitions. There can be no assurance that any financing or business development initiatives can be realized by the Company, or if realized, what the terms may be. To the extent that we raise capital through the sale of equity, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Further, if the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates.</span></div>
	us-gaap	Net Income Loss NetIncomeLoss	200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34000000.0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81900000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	23037000	usd
CY2024Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	17575000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5462000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5546257	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5462000	usd
CY2024Q3	avtx	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-36025000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30563000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5546257	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5237780	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10784037	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.83
	us-gaap	Net Income Loss NetIncomeLoss	210000	usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	177000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	33000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2491114	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	33000	usd
	avtx	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-148071000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-148038000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2491114	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	4049849	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6540963	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-22.63
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5228000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5228000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194851	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	194851	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-26.83
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-26.83
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23376000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23376000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101173	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101173	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-231.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-231.05
CY2024Q3	us-gaap	Share Price SharePrice	9.50
CY2024Q2	us-gaap	Share Price SharePrice	12.47
CY2024Q1	us-gaap	Share Price SharePrice	21.75
CY2024Q3	avtx	Lessee Operating Lease Number Of Leased Properties LesseeOperatingLeaseNumberOfLeasedProperties	2	property
	avtx	Lessee Operating Lease Remaining Lease Team LesseeOperatingLeaseRemainingLeaseTeam	P3Y10M24D
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1139000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1329000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	550000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	537000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1083000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1366000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1633000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1903000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.090
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	104000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	97000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	326000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	350000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	136000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	553000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	563000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	259000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	201000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	207000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1936000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	303000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1633000	usd
CY2024Q3	avtx	Accrued Research And Development AccruedResearchAndDevelopment	775000	usd
CY2023Q4	avtx	Accrued Research And Development AccruedResearchAndDevelopment	352000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2192000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	580000	usd
CY2024Q3	avtx	Accrued Selling General And Administrative Expenses AccruedSellingGeneralAndAdministrativeExpenses	386000	usd
CY2023Q4	avtx	Accrued Selling General And Administrative Expenses AccruedSellingGeneralAndAdministrativeExpenses	830000	usd
CY2024Q3	avtx	Sale Of Stock Transaction Costs Current SaleOfStockTransactionCostsCurrent	1734000	usd
CY2023Q4	avtx	Sale Of Stock Transaction Costs Current SaleOfStockTransactionCostsCurrent	0	usd
CY2024Q3	avtx	Commercial Operations Current CommercialOperationsCurrent	1155000	usd
CY2023Q4	avtx	Commercial Operations Current CommercialOperationsCurrent	1873000	usd
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	241000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	550000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	537000	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7033000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4172000	usd
CY2024Q3	avtx	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2024Q3	avtx	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
	avtx	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1848000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	953000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2948000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2701000	usd
CY2024Q1	avtx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease	174	shares
CY2024Q3	avtx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease	233920	shares
CY2019Q3	avtx	Royalty Agreement Payment Received RoyaltyAgreementPaymentReceived	2000000	usd
CY2019Q3	avtx	Royalty Agreement Period After Public Launch To Terminate Agreement RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement	P3Y
CY2019Q3	avtx	Royalty Agreement Buyout Option Percentage Of Net Present Value Of Royalty Payments RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments	0.75

Files In Submission

Name	View Source	Status
0001628280-24-045965-index-headers.html	Edgar Link	pending
0001628280-24-045965-index.html	Edgar Link	pending
0001628280-24-045965.txt	Edgar Link	pending
0001628280-24-045965-xbrl.zip	Edgar Link	pending
avtx-20240930.htm	Edgar Link	pending
avtx-20240930_cal.xml	Edgar Link	unprocessable
avtx-20240930.xsd	Edgar Link	pending
avtx-20240930_g1.jpg	Edgar Link	pending
avtx-20240930_def.xml	Edgar Link	unprocessable
avtx-20240930_htm.xml	Edgar Link	completed
ex-104nonxemplyoeedirector.htm	Edgar Link	pending
ex-3113q2024.htm	Edgar Link	pending
ex-3123q2024.htm	Edgar Link	pending
ex-3213q2024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
avtx-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
avtx-20240930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2024 Q4 Form 10-Q Financial Statement

#000162828024045965 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2024 Q4 Form 10-Q Financial Statement

#000162828024045965 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx